Every Form 4 that X4 Pharmaceuticals, Inc. (XFOR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow XFOR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XFOR filings page.
X4 Pharmaceuticals, Inc. president John Volpone reported selling 24,576 shares of common stock on August 12, 2026 at a weighted average price of $4.44 per share, in transactions ranging from $4.33–$4.55, to cover a personal income tax obligation upon settlement of a restricted stock unit award. Following these sales, he directly holds 265,305 shares, of which 193,254 shares represent restricted stock units.
X4 Pharmaceuticals, Inc. Executive Chairman Adam R. Craig reported selling 47,436 shares of common stock on August 12, 2026 in an open-market transaction at a weighted average price of $4.4445 per share, with individual trade prices ranging from $4.33 to $4.55. According to the disclosure, the sale was made to cover personal income tax obligations arising from the settlement of a restricted stock unit award. Following this transaction, Craig directly held 328,651 shares of common stock, including 193,254 shares represented by restricted stock units.
X4 Pharmaceuticals Chief Financial Officer David Kirske sold 8,543 shares of common stock in an open-market transaction. The shares were sold at a weighted average price of $4.2641 per share, in multiple trades between $4.21 and $4.31.
According to the filing, the sale was made to cover a personal income tax obligation arising from the settlement of a restricted stock unit award. After this transaction, Kirske directly owns 167,750 shares of X4 Pharmaceuticals common stock, including 96,627 shares represented by restricted stock units.
X4 Pharmaceuticals director Kelly Gold received a stock option grant as part of compensation. The award covers 110,000 shares of common stock with an exercise price of $4.085 per share and expires on July 1, 2036. According to the disclosure, these options were granted at no cost on the grant date and will vest in full on the one-year anniversary of the grant date, as long as Gold continues providing services through that date. Following this award, Gold is reported to hold stock options covering 110,000 shares directly.
X4 Pharmaceuticals Chief Financial Officer David Kirske reported an open-market sale of common stock. On May 12, 2026, he sold 16,961 shares of X4 Pharmaceuticals stock at a weighted average price of $4.2934 per share. According to the footnotes, this sale was made to cover a personal income tax obligation arising from the settlement of a restricted stock unit award, making it a largely tax-driven transaction rather than a discretionary portfolio move. After the sale, Kirske directly owned 176,293 shares, of which 128,836 shares are in the form of restricted stock units, so he continues to hold a substantial equity stake in the company.
X4 Pharmaceuticals director Bridger Gary received a new stock option grant. On 01/01/2026, he was awarded options to purchase 110,000 shares of X4 Pharmaceuticals common stock at an exercise price of $4.00 per share, expiring on 01/01/2036.
The options will vest in full only if stockholders approve an increase in the share reserve under the company’s Amended and Restated 2017 Equity Incentive Plan at the company’s 2026 annual meeting of stockholders, and if he continues providing services through that date. This filing reports an equity-based compensation grant rather than a share sale.
X4 Pharmaceuticals (XFOR) Executive Chairman, also a director, reported a grant of stock options for 2,329,154 shares at an exercise price of $1.42 per share. The options were granted on August 12, 2025 and became eligible to vest after a performance-based condition was satisfied on October 29, 2025.
One third of the shares underlying the option vest on August 12, 2026, with the remainder vesting in equal monthly installments over the following 24 months, subject to continued service. The options expire on August 12, 2035.
X4 Pharmaceuticals (XFOR) reported an insider equity award. The company’s President filed a Form 4 disclosing stock options to purchase 2,329,154 shares at an exercise price of $1.42. The options were granted on August 12, 2025 and became subject to reporting when a performance-based vesting condition was satisfied on October 29, 2025.
One third of the shares subject to the option will vest on August 12, 2026, with the remaining shares vesting in equal monthly installments over the following 24 months, contingent on continued service. The options expire on August 12, 2035. Following the reported transaction, 2,329,154 derivative securities were beneficially owned, held directly.
X4 Pharmaceuticals (XFOR) filed a Form 4 reporting a stock option grant to its Chief Financial Officer, David Kirske. The filing lists 1,552,769 stock options with an exercise price of $1.42 and an expiration date of 08/12/2035.
According to the disclosure, the options were granted on 08/12/2025 and were subject to a performance-based vesting condition that was satisfied on 10/29/2025. One third of the shares subject to the option will vest on 08/12/2026, with the remainder vesting in equal monthly installments over the following 24 months, contingent on continued service. Following the reported transaction, 1,552,769 derivative securities are shown as beneficially owned, held directly.
X4 Pharmaceuticals (XFOR) reported an insider purchase by its Executive Chairman and Director. On 10/23/2025, the insider bought 86,206 shares of common stock at $2.90 per share, as disclosed on Form 4.
The filing notes the shares were purchased in connection with the company’s public offering. Following the transaction, the insider beneficially owned 376,087 shares, held directly.